PURPOSE: Human urine is an ideal candidate for use in clinical diagnostics. It is easily available, as untrained personnel can collect it. It correlates well with the pathophysiology of a number of diseases, making it a useful source for clinical proteomics. EXPERIMENTAL DESIGN: In this article, we give an update of the human urinary peptide database derived from over 13,000 data sets of CE-MS by now. RESULTS: Urine samples from both patients and healthy subjects were analyzed by CE-MS; these included 47 different pathophysiological conditions. Besides defining biomarkers by their experimental parameters, information on their sequences provides fundamental data into the pathological pathways of diseases. Therefore, we have sequenced 953 urinary peptides by using state-of-the-art top-down MS/MS. Identified biomarkers of all clinical proteomic CE-MS studies including their regulation are also listed in this work. CONCLUSIONS AND CLINICAL RELEVANCE: Biomarker discovery can be used in the management of a wide range of diseases, by combining these data sets of the database. Taking this approach, we can reveal details, at a molecular level, on the pathogenesis of a number of diseases, in particular those associated with urine production and excretion.
PURPOSE:Human urine is an ideal candidate for use in clinical diagnostics. It is easily available, as untrained personnel can collect it. It correlates well with the pathophysiology of a number of diseases, making it a useful source for clinical proteomics. EXPERIMENTAL DESIGN: In this article, we give an update of the human urinary peptide database derived from over 13,000 data sets of CE-MS by now. RESULTS: Urine samples from both patients and healthy subjects were analyzed by CE-MS; these included 47 different pathophysiological conditions. Besides defining biomarkers by their experimental parameters, information on their sequences provides fundamental data into the pathological pathways of diseases. Therefore, we have sequenced 953 urinary peptides by using state-of-the-art top-down MS/MS. Identified biomarkers of all clinical proteomic CE-MS studies including their regulation are also listed in this work. CONCLUSIONS AND CLINICAL RELEVANCE: Biomarker discovery can be used in the management of a wide range of diseases, by combining these data sets of the database. Taking this approach, we can reveal details, at a molecular level, on the pathogenesis of a number of diseases, in particular those associated with urine production and excretion.
Authors: Justyna Siwy; Joost P Schanstra; Angel Argiles; Stephan J L Bakker; Joachim Beige; Petr Boucek; Korbinian Brand; Christian Delles; Flore Duranton; Beatriz Fernandez-Fernandez; Marie-Luise Jankowski; Mohammad Al Khatib; Thomas Kunt; Maria Lajer; Ralf Lichtinghagen; Morten Lindhardt; David M Maahs; Harald Mischak; William Mullen; Gerjan Navis; Marina Noutsou; Alberto Ortiz; Frederik Persson; John R Petrie; Johannes M Roob; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L Serra; Janet Snell-Bergeon; Goce Spasovski; Olivera Stojceva-Taneva; Matias Trillini; Heiko von der Leyen; Brigitte M Winklhofer-Roob; Petra Zürbig; Joachim Jankowski Journal: Nephrol Dial Transplant Date: 2014-03-02 Impact factor: 5.992
Authors: Manuel Wallbach; Petra Zürbig; Hassan Dihazi; Gerhard A Müller; Rolf Wachter; Joachim Beige; Michael J Koziolek; Harald Mischak Journal: J Clin Hypertens (Greenwich) Date: 2018-09-10 Impact factor: 3.738
Authors: Justyna Siwy; Petra Zürbig; Angel Argiles; Joachim Beige; Marion Haubitz; Joachim Jankowski; Bruce A Julian; Peter G Linde; David Marx; Harald Mischak; William Mullen; Jan Novak; Alberto Ortiz; Frederik Persson; Claudia Pontillo; Peter Rossing; Harald Rupprecht; Joost P Schanstra; Antonia Vlahou; Raymond Vanholder Journal: Nephrol Dial Transplant Date: 2017-12-01 Impact factor: 5.992